Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BioDelivery Sciences and Meda expand distribution deal

This article was originally published in Scrip

Executive Summary

BioDelivery Sciences(BDSI) and Medahave expanded their commercial partnership. The Swiss company now has the global rights to distribute BioDelivery's lead product Onsolis (fentanyl buccal soluble film) in all countries except Taiwan and South Korea in return for $3 million. BDSI had previously licensed to Meda the rights to distribute Onsolis, a treatment for breakthrough pain in opioid-tolerant patients with cancer, in the US, Canada, Mexico and Europe. Meda will pay BDSI a $3 million advance on the anticipated $30 million milestone Meda owes for Onsolis. BDSI expects Onsolis to receive approval from the US FDA during the second quarter.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts